Explore

Trendline Trendline
PureTech's LYT-200 Shows Promise in Phase 1b Trial for High-Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia

PureTech's LYT-200 Shows Promise in Phase 1b Trial for High-Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia

PureTech's LYT-200 Shows Promise in Phase 1b Trial for High-Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia
Trendline Trendline
Inhibrx Announces Webcast for Clinical Update on Ozekibart in Colorectal Cancer

Inhibrx Announces Webcast for Clinical Update on Ozekibart in Colorectal Cancer

Inhibrx Announces Webcast for Clinical Update on Ozekibart in Colorectal Cancer
Trendline Trendline
FDA Grants Fast Track Designation to Debiopharm's Ovarian Cancer Therapy

FDA Grants Fast Track Designation to Debiopharm's Ovarian Cancer Therapy

FDA Grants Fast Track Designation to Debiopharm's Ovarian Cancer Therapy
Trendline Trendline
FDA Grants Star Therapeutics Rare Pediatric and Breakthrough Therapy Designations for Von Willebrand Disease Treatment

FDA Grants Star Therapeutics Rare Pediatric and Breakthrough Therapy Designations for Von Willebrand Disease Treatment

FDA Grants Star Therapeutics Rare Pediatric and Breakthrough Therapy Designations for Von Willebrand Disease Treatment
Trendline Trendline
Star Therapeutics Gains FDA Designations for VGA039 in Von Willebrand Disease Treatment

Star Therapeutics Gains FDA Designations for VGA039 in Von Willebrand Disease Treatment

Star Therapeutics Gains FDA Designations for VGA039 in Von Willebrand Disease Treatment
Trendline Trendline
Incyte Presents Phase 3 Tafasitamab Data at ASCO 2026, Supporting Global Regulatory Submissions

Incyte Presents Phase 3 Tafasitamab Data at ASCO 2026, Supporting Global Regulatory Submissions

Incyte Presents Phase 3 Tafasitamab Data at ASCO 2026, Supporting Global Regulatory Submissions
Trendline Trendline
Forlong Biotechnology to Present Clinical Data on FL115 at ASCO 2026

Forlong Biotechnology to Present Clinical Data on FL115 at ASCO 2026

Forlong Biotechnology to Present Clinical Data on FL115 at ASCO 2026
Trendline Trendline
Forlong Biotechnology to Present Clinical Data on FL115 for Advanced Solid Tumors at ASCO 2026

Forlong Biotechnology to Present Clinical Data on FL115 for Advanced Solid Tumors at ASCO 2026

Forlong Biotechnology to Present Clinical Data on FL115 for Advanced Solid Tumors at ASCO 2026
Trendline Trendline
NEOK Bio Highlights Bispecific Antibody Drug Conjugate Pipeline at AACR 2026

NEOK Bio Highlights Bispecific Antibody Drug Conjugate Pipeline at AACR 2026

NEOK Bio Highlights Bispecific Antibody Drug Conjugate Pipeline at AACR 2026
Trendline Trendline
FDA Grants Priority Review for KEYTRUDA and Padcev Combination for Muscle-Invasive Bladder Cancer

FDA Grants Priority Review for KEYTRUDA and Padcev Combination for Muscle-Invasive Bladder Cancer

FDA Grants Priority Review for KEYTRUDA and Padcev Combination for Muscle-Invasive Bladder Cancer
Trendline Trendline
Debiopharm's Ovarian Cancer Treatment Receives FDA Fast Track Designation

Debiopharm's Ovarian Cancer Treatment Receives FDA Fast Track Designation

Debiopharm's Ovarian Cancer Treatment Receives FDA Fast Track Designation
Trendline Trendline
EpiBiologics Initiates Phase 1 Study of EPI-326 for EGFR-Driven Cancers

EpiBiologics Initiates Phase 1 Study of EPI-326 for EGFR-Driven Cancers

EpiBiologics Initiates Phase 1 Study of EPI-326 for EGFR-Driven Cancers